H. Parker
Vermögen: 212 458 $ am 30.09.2026
Vermögen: 212 458 $ am 30.09.2026
Ms. H.
S.
Parker is an Independent Director at Codexis, Inc., a Chairman at Sangamo Therapeutics, Inc. and a Principal at Parker Bioconsulting.
She is on the Board of Directors at Codexis, Inc. and Global Partnerships.
Ms. Parker was previously employed as an Independent Director by Armata Pharmaceuticals, Inc., an Independent Director by Impel Pharmaceuticals, Inc., a Chief Executive Officer & Director by Infectious Disease Research Institute, an Independent Director by OncoGenex Pharmaceuticals, Inc., an Independent Director by Achieve Life Sciences, Inc., a Chief Executive Officer & Director by Targeted Genetics Corp., a President & Director by Receptech Corp., a President, Chief Executive Officer & Director by Immunex Corp., and a Chairman by C3 Jian LLC.
She also served on the board at Inventprise, Inc., StrideBio, Inc., Nexgenia, Inc., Neose Technologies, Inc., Biotechnology Innovation Organization, OncoGenex Technologies, Inc. and Regence BlueShield.
She received her undergraduate degree from the University of Washington and an MBA from the University of Washington.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CODEXIS, INC. 0.13% | 17.06.2026 | 143’583 ( 0.13% ) | 199 580 $ | 30.09.2026 |
| 20.04.2026 | 87’600 ( 0.02% ) | 12 877 $ | 30.09.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Vorsitzender | 01.06.2017 |
| CODEXIS, INC. | Direktor/Vorstandsmitglied | 16.12.2022 |
Global Partnerships
Global Partnerships Financial ConglomeratesFinance Invests in partnerships with local organizations that use market-based solutions for people living in poverty | Direktor/Vorstandsmitglied | - |
Parker Bioconsulting | Corporate Officer/Principal | 01.01.2009 |
| Unternehmen | Position | Ende |
|---|---|---|
Inventprise LLC
Inventprise LLC Pharmaceuticals: MajorHealth Technology Manufactures vaccines | Direktor/Vorstandsmitglied | 01.04.2025 |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Develops gene therapies | Direktor/Vorstandsmitglied | 01.12.2023 |
| IPI LEGACY LIQUIDATION CO | Direktor/Vorstandsmitglied | 10.04.2023 |
| ACHIEVE LIFE SCIENCES, INC. | Direktor/Vorstandsmitglied | 11.05.2021 |
| ARMATA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 08.12.2020 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 21 |
|---|---|
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Manufactures, markets, and researches therapeutic products | Health Technology |
Receptech Corp.
Receptech Corp. Medical DistributorsDistribution Services Sells Immunex products | Distribution Services |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology Develops and commercializes novel bacteriophage-based therapeutics | Health Technology |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic protein drugs | Health Technology |
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Codexis, Inc.
Codexis, Inc. Chemicals: SpecialtyProcess Industries Develops biocatalytic chemical processes | Process Industries |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
C3 Jian LLC
C3 Jian LLC BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that focuses on development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections | Health Technology |
Impel Pharmaceuticals, Inc.
Impel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a late-stage biopharmaceutical company focused on developing transformative therapies for central nervous system disorders | Health Technology |
Nexgenia, Inc.
Nexgenia, Inc. Medical SpecialtiesHealth Technology Develops stimuli-responsive polymers and polymer-containing magnetic nanoparticles | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OncoGenex Technologies, Inc.
OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Regence BlueShield
Regence BlueShield Life/Health InsuranceFinance Provides health insurance services | Finance |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies that address treatment resistance in cancer patients | Health Technology |
Infectious Disease Research Institute
Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases | Commercial Services |
Global Partnerships
Global Partnerships Financial ConglomeratesFinance Invests in partnerships with local organizations that use market-based solutions for people living in poverty | Finance |
Inventprise LLC
Inventprise LLC Pharmaceuticals: MajorHealth Technology Manufactures vaccines | Health Technology |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Develops gene therapies | Health Technology |
Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes cytisinicline for smoking cessation and nicotine addiction | Health Technology |
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company focused on the development and commercialization of novel targeted antimicrobials | Health Technology |
Parker Bioconsulting |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen